NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

AMH for the Identification of PCOM in PCOS Diagnosis

UnknownN/A

Sponsor: Oulu University Hospital

Conditions: Polycystic Ovary Syndrome

Countries: Finland

The purpose of this study is to validate the anti-müllerian hormone (AMH) cut-off established and validated in the APHRODITE study, for the determination of PCOM as part of the diagnosis of PCOS, using the Elecsys AMH Plus immunoassay.

Eligibility overview

Sex: FEMALE

Age: 32 Years to 37 Years

Healthy volunteers: Yes

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Female
* Born July 1985-Dec 1987 in Northern Finland
* Signed informed consent regarding ROCHE collaboration

Exclusion Criteria:

* Unwilling to undergo gynecological examination including transvaginal ultrasound (TVUS)
* Unwilling to have blood drawn
* Pregnancy

Locations (1)

Oulu, Finland